Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Multiple Myeloma 7Lymphoma 6Leukemia 6Myelodysplastic Syndromes 5Leukemia, Lymphocytic, Chronic, B-Cell 5Hematologic Neoplasms 5Primary Myelofibrosis 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Neoplasms, Plasma Cell 3Myeloproliferative Disorders 3Lymphoma, Non-Hodgkin 3Kidney Neoplasms 3Hodgkin Disease 3Wilms Tumor 2Thrombocythemia, Essential 2Rhabdomyosarcoma 2Recurrence 2Polycythemia Vera 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Neoplasms 2Lymphoma, T-Cell 2Lymphoma, Large B-Cell, Diffuse 2Graft vs Host Disease 2Carcinoma, Renal Cell 2Carcinoma, Ovarian Epithelial 2Thrombocytopenia 1Testicular Neoplasms 1

Interventions

fludarabine 2fludarabine phosphate 1carfilzomib 1Whole-Body Irradiation 1Stem Cell Transplantation 1Melphalan 1Filgrastim 1Cyclosporine 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Leukemia, Plasma Cell × Stem Cell Transplantation × Clear all
NCT00615589 2016-04-04

Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen

University of Michigan Rogel Cancer Center

Phase 2 Terminated
22 enrolled 9 charts
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡